Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

547
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
547
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Obesity01:24

Obesity

1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

300
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
300
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.

Obesity science & practice·2026
Same author

Erratum: Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.

Obesity pillars·2026
Same author

Corrigendum to "Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society [Obesity Pillars 15 (2025) 100181].

Obesity pillars·2026
Same author

Engagement and Weight Change in an Online Weight Management Program in Clinical Settings: An Implementation Project.

Journal of general internal medicine·2026
Same author

Uncovering Gaps in Obesity Medicine Competencies: Insights from Ten U.S. Medical Schools.

Medical science educator·2026
Same author

Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.

Journal of clinical gastroenterology·2026

Related Experiment Video

Updated: Feb 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K

Updates on obesity pharmacotherapy.

Amanda Velazquez1, Caroline M Apovian2

  • 1Bariatric Medicine and Internal Medicine, Kaiser Permanente Medical Center, Los Angeles, California.

Annals of the New York Academy of Sciences
|January 30, 2018
PubMed
Summary
This summary is machine-generated.

Obesity management requires a multidisciplinary approach, including behavioral changes and new FDA-approved long-term pharmacotherapies. This review details updated obesity pharmacotherapy options and their integrated use.

Keywords:
obesityoverweightpharmacotherapyweight loss

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.5K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity is a complex, chronic disease requiring long-term management strategies.
  • Historically, obesity treatments were limited to short-term interventions due to insufficient biological understanding.
  • Recent advancements recognize obesity as a medical condition, leading to new long-term therapeutic options.

Purpose of the Study:

  • To provide an updated review of pharmacotherapy for chronic obesity management.
  • To discuss newly approved weight loss medications by the Food and Drug Administration (FDA).
  • To explore the comanagement of obesity with metabolic conditions and its integration with mental health and reproductive health considerations.

Main Methods:

  • Literature review of recent studies and FDA approvals related to obesity pharmacotherapy.
  • Analysis of pharmacological agents for long-term obesity management.
  • Examination of treatment strategies for obesity comorbidities and special populations.

Main Results:

  • Several new weight loss medications have been approved by the FDA for chronic obesity management.
  • Pharmacotherapy is increasingly recognized as a key component of long-term obesity treatment alongside behavioral changes.
  • Integration of obesity pharmacotherapy with management of type 2 diabetes, hypertension, dyslipidemia, mental illness, and reproductive health is highlighted.

Conclusions:

  • Modern obesity management emphasizes a chronic, multidisciplinary approach incorporating pharmacotherapy.
  • Newer FDA-approved medications offer long-term solutions for weight management.
  • Personalized prescribing, considering comorbidities and specific patient needs, is crucial for effective obesity treatment.